Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | PLA2G6 | O60733 | 2/20 | 0.41 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.41 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.38 |
| ▸ | FASN | P49327 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4666667 | 0.82 | CYP3A4 (0.47) | CYP3A4APPFASN | |
| SCHEMBL4663335 | 0.81 | CYP3A4 (0.48) | CYP3A4 | |
| SCHEMBL4496886 | 0.78 | CYP3A4 (0.43) | CYP3A4PLA2G6PLA2G4AFASN | |
| SCHEMBL18214368 | 0.76 | CYP3A4 (0.54) | CYP3A4PLA2G6PLA2G4AAPPFASN | |
| SCHEMBL9016220 | 0.75 | CYP3A4 (0.53) | CYP3A4PLA2G6PLA2G4AAPPFASN | |
| SCHEMBL10358232 | 0.71 | CYP3A4 (0.46) | CYP3A4APP | |
| SCHEMBL10531250 | 0.71 | CYP3A4 (0.46) | CYP3A4APP | |
| SCHEMBL8985145 | 0.70 | PLA2G6 (0.44) | CYP3A4PLA2G6PLA2G4AFASN | |
| SCHEMBL7978253 | 0.70 | PLA2G6 (0.58) | PLA2G6PLA2G4AFASN | |
| Dihydrokawain SCHEMBL5672433 | 0.69 | CYP3A4 (1.00) | CYP3A4FASN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080132562-A1 | TETRONIC AND TETRAMIC ACIDS | GODEL THIERRY | 2008-06-05 | — | — | US | disclosed |
| EP-1689729-A1 | TETRONIC AND TETRAMIC ACIDS AS INHIBITORS OF BETA-SECREASE | F. Hoffmann-La Roche AG (CH) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005058857-A1 | TETRONIC AND TETRAMIC ACIDS AS INHIBITORS OF BETA-SECREASE | F. HOFFMANN-LA ROCHE AG (CH) | 2005-06-30 | — | — | WO | disclosed |
| US-20050119329-A1 | Tetronic and tetramic acids | HOFFMANN-LA ROCHE INC. | 2005-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132562-A1 | TETRONIC AND TETRAMIC ACIDS | BACE1, PSEN1, BACE2 | CYP3A4 2131/4885PLA2G6 1155/4885PLA2G4A 2775/4885 |
| US-20050119329-A1 | Tetronic and tetramic acids | BACE1, PSEN1, BACE2 | CYP3A4 2131/4885PLA2G6 1155/4885PLA2G4A 2775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.